CNSide Diagnostics, LLC Partners with Humana Inc. to Expand Coverage of CNSide® CSF Tumor Cell Enumeration Test to 67 Million People

CNSide Diagnostics signs agreement with Humana to provide CSF tumor cell testing, extending coverage to 67 million people.

Quiver AI Summary

CNSide Diagnostics, LLC, a subsidiary of Plus Therapeutics, Inc., announced a national agreement with Humana, Inc. to provide its CNSide® Cerebrospinal Fluid Tumor Cell Enumeration test, effective October 29, 2025, which will cover approximately 16 million individuals across the U.S. This agreement expands the total coverage for the test to 67 million people and enhances the company's ability to offer rapid diagnosis and treatment monitoring for patients with leptomeningeal metastases. The CNSide test has demonstrated superior clinical utility compared to standard care, with high sensitivity and specificity, influencing treatment decisions in 90% of cases. The CNSide® CSF Assay Platform aims to improve management of patients with metastatic tumors in the central nervous system, with more than 11,000 tests performed since 2020 at over 120 U.S. cancer institutions.

Potential Positives

The signing of a national agreement with Humana covers approximately 16 million people, expanding accessibility to the CNSide® CSF Tumor Cell Enumeration (TCE) test.
This agreement increases total policy coverage for the CNSide CSF TCE LDT to 67 million people, significantly enhancing the market reach of the test.
The CNSide® CSF Assay Platform has demonstrated high sensitivity (92%) and specificity (95%), indicating its effectiveness in diagnosing and managing patients with leptomeningeal metastases.
Over 11,000 CNSide® tests have been performed since 2020, showcasing established demand and real-world efficacy influencing treatment decisions in 90% of cases.

Potential Negatives

Potential over-reliance on a single agreement with Humana could expose the company to risks if the partnership does not meet expectations or if coverage terms change.
The mention of forward-looking statements raises caution regarding the uncertainty of future revenue and profitability, implying potential financial instability.
The absence of specific details on the commercial launch timeline and revenue projections may lead to skepticism among investors regarding the company's growth prospects.

FAQ

What is the CNSide® CSF Tumor Cell Enumeration (TCE) test?

The CNSide® CSF TCE test is a laboratory-developed test that enumerates tumor cells in cerebrospinal fluid, aiding in cancer diagnosis and treatment.

How many people are covered by the CNSide® CSF test?

The CNSide® CSF test is now covered for approximately 67 million people across the United States, following a new agreement with Humana, Inc.

What is the sensitivity and specificity of the CNSide® CSF test?

The CNSide® CSF test shows a high sensitivity of 92% and specificity of 95%, influencing treatment decisions in 90% of cases.

Where can healthcare professionals access the CNSide® test?

The CNSide® CSF test is exclusively available through CNSide Diagnostics, LLC, provided to healthcare professionals in the U.S.

What is Plus Therapeutics, Inc. focused on?

Plus Therapeutics, Inc. develops targeted radiotherapeutics for difficult-to-treat central nervous system cancers, improving clinical outcomes through innovative technologies.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$PSTV Insider Trading Activity

$PSTV insiders have traded $PSTV stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $PSTV stock by insiders over the last 6 months:

ROBERT P LENK purchased 110,000 shares for an estimated $53,779
ANDREW JOHN HUGH MACINTYRE SIMS (Chief Financial Officer) purchased 20,000 shares for an estimated $10,200

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$PSTV Hedge Fund Activity

We have seen 18 institutional investors add shares of $PSTV stock to their portfolio, and 13 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

VANGUARD GROUP INC added 1,414,286 shares (+4346.2%) to their portfolio in Q3 2025, for an estimated $966,947
ALTIUM CAPITAL MANAGEMENT LLC added 918,914 shares (+inf%) to their portfolio in Q3 2025, for an estimated $628,261
GEODE CAPITAL MANAGEMENT, LLC added 762,074 shares (+1489.1%) to their portfolio in Q3 2025, for an estimated $521,029
UBS GROUP AG added 536,236 shares (+611.9%) to their portfolio in Q3 2025, for an estimated $366,624
BLACKROCK, INC. added 462,429 shares (+6644.1%) to their portfolio in Q3 2025, for an estimated $316,162
STATE STREET CORP added 341,893 shares (+inf%) to their portfolio in Q3 2025, for an estimated $233,752
NORTHERN TRUST CORP added 265,489 shares (+inf%) to their portfolio in Q3 2025, for an estimated $181,514

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$PSTV Analyst Ratings

Wall Street analysts have issued reports on $PSTV in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 11/03/2025
D. Boral Capital issued a "Buy" rating on 10/31/2025
Ascendiant Capital issued a "Buy" rating on 10/06/2025
Maxim Group issued a "Buy" rating on 08/18/2025

To track analyst ratings and price targets for $PSTV, check out Quiver Quantitative's $PSTV forecast page.

$PSTV Price Targets

Multiple analysts have issued price targets for $PSTV recently. We have seen 4 analysts offer price targets for $PSTV in the last 6 months, with a median target of $4.0.

Here are some recent targets:

Sean Lee from HC Wainwright & Co. set a target price of $2.0 on 11/03/2025
Jason Kolbert from D. Boral Capital set a target price of $5.0 on 10/31/2025
Edward Woo from Ascendiant Capital set a target price of $21.0 on 10/06/2025
Jason McCarthy from Maxim Group set a target price of $3.0 on 08/18/2025

Full Release

HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), announced today that it has signed a national agreement with Humana, Inc. (NYSE: HUM ), effective October 29, 2025, covering approximately 16 million people throughout the United States, to provide the CNSide ^® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) laboratory developed test (LDT). This brings CNSide CSF TCE LDT total policy coverage to 67 million people.

The CNSide ^® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The superior clinical utility of CNSide ^® over standard of care has been shown in 9 peer-reviewed publications, the FORESEE clinical trial, and has been validated in the market through real-world use.

More than 11,000 CNSide ^® tests have been performed at over 120 U.S. cancer institutions since 2020, delivering high sensitivity (92%) and specificity (95%), while influencing treatment decisions in 90% of cases.

This test is available exclusively through CNSide Diagnostics, LLC. as a testing service provided to health care professionals in the U.S.

About CNSide Diagnostics, LLC
CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide ^® , designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide ^® CSF Assay Platform enables quantitative analysis of the cerebrospinal fluid that informs and improves the management of patients with leptomeningeal metastases. For more information, visit https://www.cnside-dx.com/ .

About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://www.plustherapeutics.com .

About Humana

Humana Inc. (NYSE: HUM ) is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.

Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential market for the CNSide CSF Assay, the timing in which the CNSide CSF Assay is commercially launched and commercialization is expanded, revenue and corporate profitability expectations including support reimbursements and payments for the CNSide CSF Assay, the development and utility of the CNSide CSF Assay and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates.

Investor Contact
CORE IR
[email protected]